Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma
CONCLUSION: Efficacy and safety of sorafenib did not differ significantly between younger and older patients with HCC. Our data suggest that age alone should not restrict clinical decision-making for patients with advanced HCC.
Source: Clinics - Category: General Medicine Source Type: research
More News: Cancer & Oncology | Carcinoma | General Medicine | Hepatocellular Carcinoma | Liver Cancer | Toxicology